Fund moves
100 tracked managers disclosed the same change for Q1 2026. From a 13F filed May 15, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Apr 23, 2026 · Filed Apr 27, 2026
The CFO of Abbott Laboratories paid $201K out of pocket for Abbott Laboratories shares. 2 other people at Abbott Laboratories bought some too, in the same month.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$201,300
Shares × reported transaction price
$100K–$500K
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
3 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals about 2.7% of the average reported total pay of the company's named executive officers other than the CEO, fiscal 2025 ($7.46M)
An average across the officers named in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-03-13. This person may not be one of them, so it is not their own pay. A size comparison, not a judgement
7 days after results of Apr 16, 2026, 84 days before results of Jul 16, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $92.48 on Apr 23, 2026, within 1% of its 52-week low, after a 16% drop over the previous 30 trading days
52-week range $91.70 (Apr 22, 2026) to $138.08 (Jun 24, 2025), 2% of the way up, from 251 adjusted closes. 30 trading days earlier: $110.25 on Mar 11, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
Traded 1 day before ABT filed an 8-K: changed a top executive or board member, and changed its bylaws, charter or fiscal year (and 1 more item) (Apr 24, 2026). Philip P Boudreau's first open-market purchase of ABT in filings since 2006
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −7.1% | +1.7% | −8.8% |
| 30 days | −8.1% | +6.0% | −14.1% |
| 90 days | +11.3% | +3.9% | +7.5% |
| 180 days | +11.7% | +7.5% | +4.2% |
Past results only. Not a forecast.
Fund moves
100 tracked managers disclosed the same change for Q1 2026. From a 13F filed May 15, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
11 tracked managers disclosed the same change for Q1 2026. From a 13F filed May 15, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
100 tracked managers disclosed the same change for Q1 2026. From a 13F filed May 15, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.